Determination of mean recency period for estimation of HIV type 1 Incidence with the BED-capture EIA in persons infected with diverse subtypes.

The IgG capture BED enzyme immunoassay (BED-CEIA) was developed to detect recent HIV-1 infection for the estimation of HIV-1 incidence from cross-sectional specimens. The mean time interval between seroconversion and reaching a specified assay cutoff value [referred to here as the mean recency period (ω)], an important parameter for incidence estimation, is determined for some HIV-1 subtypes, but testing in more cohorts and new statistical methods suggest the need for a revised estimation of ω in different subtypes. A total of 2927 longitudinal specimens from 756 persons with incident HIV infections who had been enrolled in 17 cohort studies was tested by the BED-CEIA. The ω was determined using two statistical approaches: (1) linear mixed effects regression (ω(1)) and (2) a nonparametric survival method (ω(2)). Recency periods varied among individuals and by population. At an OD-n cutoff of 0.8, ω(1) was 176 days (95% CL 164-188 days) whereas ω(2) was 162 days (95% CL 152-172 days) when using a comparable subset of specimens (13 cohorts). When method 2 was applied to all available data (17 cohorts), ω(2) ranged from 127 days (Thai AE) to 236 days (subtypes AG, AD) with an overall ω(2) of 197 days (95% CL 173-220). About 70% of individuals reached a threshold OD-n of 0.8 by 197 days (mean ω) and 95% of people reached 0.8 OD-n by 480 days. The determination of ω with more data and new methodology suggests that ω of the BED-CEIA varies between different subtypes and/or populations. These estimates for ω may affect incidence estimates in various studies.

[1]  R. Byers,et al.  Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. , 2002, AIDS research and human retroviruses.

[2]  C. Pau,et al.  Performance Characteristics of the Immunoglobulin G-Capture BED-Enzyme Immunoassay, an Assay To Detect Recent Human Immunodeficiency Virus Type 1 Seroconversion , 2004, Journal of Clinical Microbiology.

[3]  S. Lagakos,et al.  Better Control of Early Viral Replication Is Associated With Slower Rate of Elicited Antiviral Antibodies in the Detuned Enzyme Immunoassay During Primary HIV-1C Infection , 2009, Journal of acquired immune deficiency syndromes.

[4]  B. Branson,et al.  Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populations , 2004, AIDS.

[5]  S. Oka,et al.  Effects of low HIV type 1 load and antiretroviral treatment on IgG-capture BED-enzyme immunoassay. , 2008, AIDS research and human retroviruses.

[6]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[7]  R. Garfein,et al.  Unprotected Sexual Behavior Among Heterosexual HIV-Positive Injection Drug Using Men: Associations by Partner Type and Partner Serostatus , 2006, Journal of Urban Health.

[8]  B. Branson,et al.  Surveillance for HIV-1 incidence using tests for recent infection in resource-constrained countries , 2005, AIDS.

[9]  J. Phair,et al.  Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men. , 1987, The New England journal of medicine.

[10]  Jeremy MG Taylor,et al.  Partially parametric techniques for multiple imputation , 1996 .

[11]  C. Pau,et al.  Assessment of antibody assays for identifying and distinguishing recent from long-term HIV type 1 infection. , 2001, AIDS research and human retroviruses.

[12]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[13]  J. Mcdougal,et al.  Application of laboratory methods for estimation of HIV-1 incidence. , 2005, The Indian journal of medical research.

[14]  W. Heneine,et al.  Viral load differences in early infection with two HIV-1 subtypes , 2001, AIDS.

[15]  W. Blattner,et al.  Improved Classification of Recent HIV-1 Infection by Employing a Two-Stage Sensitive/Less-Sensitive Test Strategy , 2003, Journal of acquired immune deficiency syndromes.

[16]  C. Galli,et al.  Precision and Accuracy of a Procedure for Detecting Recent Human Immunodeficiency Virus Infections by Calculating the Antibody Avidity Index by an Automated Immunoassay-Based Method , 2002, Journal of Clinical Microbiology.

[17]  O. N. Gill,et al.  What a test for recent infection might reveal about HIV incidence in England and Wales , 2000, AIDS.

[18]  G. Molenberghs,et al.  Linear Mixed Models for Longitudinal Data , 2001 .

[19]  G. Satten,et al.  Evaluation of a sensitive/less-sensitive testing algorithm using the 3A11-LS assay for detecting recent HIV seroconversion among individuals with HIV-1 subtype B or E infection in Thailand. , 2001, AIDS research and human retroviruses.

[20]  Oliver Laeyendecker,et al.  Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. , 2008, The Journal of infectious diseases.

[21]  Punnee Pitisuttithum,et al.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. , 2006, The Journal of infectious diseases.

[22]  C. Gray,et al.  Establishing a Cohort at High Risk of HIV Infection in South Africa: Challenges and Experiences of the CAPRISA 002 Acute Infection Study , 2008, PloS one.

[23]  Robert Tibshirani,et al.  An Introduction to the Bootstrap , 1994 .

[24]  J. Desenclos,et al.  Development and Validation of an Immunoassay for Identification of Recent Human Immunodeficiency Virus Type 1 Infections and Its Use on Dried Serum Spots , 2005, Journal of Clinical Microbiology.

[25]  R. Janssen,et al.  Development of a new less-sensitive enzyme immunoassay for detection of early HIV-1 infection. , 2003, Journal of acquired immune deficiency syndromes.

[26]  G. Rutherford,et al.  Surveillance for Incident HIV Infection: New Technology and New Opportunities , 2000, Journal of acquired immune deficiency syndromes.

[27]  Ekkehard Kopp,et al.  Improved HIV-1 incidence estimates using the BED capture enzyme immunoassay , 2008, AIDS.

[28]  Kenneth H Mayer,et al.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. , 2005, The Journal of infectious diseases.

[29]  M. Goldman.  New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes , 1999 .

[30]  A. Kamali,et al.  Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa , 2007, AIDS.

[31]  J. Baeten,et al.  Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women. , 2004, The Journal of infectious diseases.

[32]  T. Granade,et al.  Modification of Rapid Human Immunodeficiency Virus (HIV) Antibody Assay Protocols for Detecting Recent HIV Seroconversion , 2005, Clinical Diagnostic Laboratory Immunology.

[33]  B. Branson,et al.  Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay. , 2006, AIDS research and human retroviruses.